We are proud to develop, produce, license and commercialise a biosimilar that meets the highest medical standards: Ranibizumab, biosimilar to Lucentis, for the treatment of e.g. age related macular degeneration AMD.
Ranibizumab is approved by the US Food and Drug Administration FDA, branded as Cimerli, the UK Medicines and Healthcare Regulatory Agency, branded as Ongavia, by the European Commission and Swissmedic, branded as Ranivisio, and by various other competent authorities worldwide.
Press releases
EC Approval FYB/Ranivisio
Aug 29, 2022
FDA approves CIMERLI, the first biosimilar interchangeable with Lucentis
Aug 03, 2022
Grant of marketing authorisation in UK
May 17, 2022
Bioeq AG and MS Pharma
Dec 14, 2021
Bioeq AG and Teva
Jun 28, 2021
Bioeq AG and Coherus
Nov 06, 2019
Now: What could your career be, our jobs, who we are, and what our product is, — thank you for being interested in Bioeq and our fantastic team.
